Standard drug treatment for Parkinson’s disease can over time induce motor complications that reduce the effectiveness of restoring mobility. These complications include abnormal involuntary movements known as dyskinesias. In a nonhuman primate model of Parkinson’s, scientists have been probing the origin of these abnormal responses to treatment, particularly dyskinesias, and have successfully tested a tactic for controlling them.